The Cancer Market Outlook to 2012

Published by: Business Insights

Published: Jan. 1, 2008 - 263 Pages

Table of Contents

The Cancer Market Outlook to 2012

Executive Summary

Patient potential

Global market analysis

Pipeline analysis

Competitive landscape

Chapter 1 Epidemiology of cancer

Summary

Introduction

Overview

Lung cancer

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Colorectal cancer

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Breast cancer

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Ovarian cancer

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Uterine and cervical cancer

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Leukemia

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Prostate cancer

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Pancreatic cancer

Overview

Diagnosis, treatment and management

Epidemiology

Forecast prevalence

Lymphomas

Overview

Diagnosis, treatment and management

Epidemiology

Forecast prevalence

Chapter 2 Global market analysis

Summary

Introduction

Market analysis by country

Trends in generics usage and licensing

Market analysis by drug class

Leading brands dynamics

Key events in the cancer market

Antineoplastics

Competitive dynamics of antineoplastics

Leading brands of antineoplastics

Antineoplastic MAb market analysis

Market dynamics

Key brands analysis

Vinka alkaloid market analysis

Market dynamics

Key brands analysis

Anti-metabolites

Market dynamics

Key brands analysis

Other antineoplastics

Market dynamics

Antineoplastic sales forecasts to 2012

Immunostimulants

Competitive dynamics of immunostimulants

Leading brands of immunostimulants

Interferon market analysis

Market dynamics

Key brands analysis

Other immunostimulants

Market dynamics

Key brand analysis

Immunostimulant sales forecasts to 2012

Cytostatic hormonal therapies

Competitive dynamics of cytostatic hormonal therapies

Leading brands of cytostatic hormonal therapies

LHRH agonists market analysis

Market dynamics

Key brands analysis

Aromatase inhibitors

Market dynamics

Key brands analysis

Anti-estrogens

Market dynamics

Key brand analysis

Anti-androgens

Cytostatic hormonal therapy sales forecasts to 2012

Total cancer market sales forecasts to 2012

Chapter 3 Pipeline analysis

Summary

Introduction

Key trends in R&D

Need for drugs with improved tumor selectivity

Increased focus on cancer vaccine pipeline

Cost containment policies emerging as barrier for drug development

The cancer pipeline

Leading drugs in development

Profiles of key pipeline products

Phase III compounds

Enzastaurin

BiovaxID

HuMax-CD20 (ofatumumab)

Recentin (cediranib)

Zactima (vandetanib)

Recently approved/marketed drugs

Tasigna (nilotinib)

Gardasil and Cervarix

Vectibix (panitumumab)

Nexavar (sorafenib)

Sutent (sunitinib)

Tykerb (lapatinib)

Pipeline forecasts

Factors affecting forecasts

Cancer therapeutic area forecasts

Chapter 4 Competitive landscape

Summary

Introduction

Company market shares

Roche

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Amgen

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Sanofi-Aventis

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

AstraZeneca

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Novartis

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Pfizer

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Schering-Plough

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Eli Lilly

Overview

Sales focus by drug class

Marketed product portfolio

R&D pipeline analysis

Strategic and growth analysis

Drivers of growth

Resistors of growth

Chapter 5 Appendix

IMS data

Antineoplastic and immunomodulating agents

L1: Cytostatics

L2: Cytostatic hormone therapy

L3: Immunostimulating agents

Licensing status as per IMS Health

Original brand

Other brand

Licensed brand

Not-coded product

Unbranded/ generic product

Index

List of Figures

Figure 1.1: Overview of cancer etiology

Figure 2.2: Worldwide cancer market share by geography, 2006

Figure 2.3: Sales of cancer brands by license type, 2005-06

Figure 2.4: Competitive dynamics of the global cancer market by drug class, 2006

Figure 2.5: Competitive dynamics of the leading brands in the global cancer market, 2005-06

Figure 2.6: Competitive dynamics of the major antineoplastic classes in the global cancer market, 2005-06

Figure 2.7: Competitive dynamics of leading brands in the antineoplastic market, 2005-06

Figure 2.8: Competitive dynamics of the major immunostimulant classes in the global cancer market, 2005-06

Figure 2.9: Competitive dynamics of the leading brands in the global cancer immunostimulant market, 2005-06

Figure 2.10: Competitive dynamics of the major cytostatic hormonal therapy classes in the global cancer market, 2005-06

Figure 2.11: Competitive dynamics of the leading brands in the global cytostatic hormonal therapy market, 2005-06

Figure 3.12: Driver and resistors in cancer R&D, 2007

Figure 3.13: Oncology pipeline by indication and stage of development, 2006

Figure 3.14: Recently launched products and late-stage R&D compounds indicated for the treatment of cancer, 2006

Figure 4.15: Competitive dynamics of the leading players in the global cancer market, 2006

Figure 4.16: Roche’s cancer sales by drug class, 2006

Figure 4.17: Amgen’s cancer sales by drug class, 2006

Figure 4.18: Sanofi-Aventis’ cancer sales by drug class, 2006

Figure 4.19: AstraZeneca’s cancer sales by drug class, 2006

Figure 4.20: Novartis’ cancer sales by drug class, 2006

Figure 4.21: Pfizer’s cancer sales by drug class, 2006

Figure 4.22: Schering-Plough’s cancer sales by drug class, 2006

Figure 4.23: Lilly’s cancer sales by drug class, 2006

List of Tables

Table 1.1: Estimated prevalence of lung cancer across the seven major markets, 2006

Table 1.2: Forecast epidemiology of lung cancer across the seven major markets, 2006-12

Table 1.3: Estimated epidemiology of colorectal cancer across the seven major markets, 2006

Table 1.4: Forecast epidemiology of colorectal cancer across the seven major markets, 2006-12

Table 1.5: Estimated epidemiology of breast cancer across the seven major markets, 2006

Table 1.6: Forecast epidemiology of breast cancer across the seven major markets, 2006-12

Table 1.7: Estimated epidemiology of ovarian cancer across the seven major markets, 2006

Table 1.8: Forecast epidemiology of ovarian cancer across the seven major markets, 2006-12

Table 1.9: Estimated epidemiology of uterine cancer across the seven major markets, 2006

Table 1.10: Forecast epidemiology of uterine cancer across the seven major markets, 2006-12

Table 1.11: Estimated epidemiology of leukemia across the seven major markets, 2006

Table 1.12: Forecast epidemiology of leukemia across the seven major markets, 2006-12

Table 1.13: Estimated epidemiology of prostate cancer across the seven major markets, 2006

Table 1.14: Forecast epidemiology of prostate cancer across the seven major markets, 2006-12

Table 1.15: Estimated epidemiology of pancreatic cancer across the seven major markets, 2006

Table 1.16: Forecast epidemiology of pancreatic cancer across the seven major markets, 2006-12

Table 1.17: Estimated epidemiology of lymphomas across the seven major markets, 2006

Table 1.18: Forecast epidemiology of lymphomas across the seven major markets, 2006-12

Table 2.19: Breakdown of the global cancer market by drug class, 2003-06

Table 2.20: Leading products in the global cancer market, 2005-06

Table 2.21: Breakdown of the global antineoplastic market by drug class,

Table 2.22: Leading therapies in the global antineoplastics market, 2005-06

Table 2.23: Antineoplastic sales forecast, 2006-12

Table 2.24: Breakdown of the global immunostimulant market by drug class, 2003-06

Table 2.25: Leading therapies in the global immunostimulant market, 2005-06

Table 2.26: Immunostimulant sales forecast, 2006-12

Table 2.27: Global cytostatic hormonal therapy market by drug class, 2003-06

Table 2.28: Leading therapies in the global cytostatic hormonal therapy market, 2005-06

Table 2.29: Cytostatic hormonal therapy sales forecast, 2006-12

Table 2.30: Cancer sales forecasts by drug class, 2006-112

Table 3.31: Cancer pipeline sales forecasts, 2006-12

Table 4.32: Leading players in the cancer market, 2005-06

Table 4.33: Roche’s cancer product portfolio, 2005-06

Table 4.34: Roche’s cancer R&D product pipeline, 2007

Table 4.35: Amgen’s cancer product portfolio, 2005-06

Table 4.36: Amgen’s cancer R&D product pipeline, 2007

Table 4.37: Sanofi-Aventis’ cancer product portfolio, 2005-06

Table 4.38: Sanofi-Aventis’ cancer R&D product pipeline, 2007

Table 4.39: AstraZeneca’s cancer product portfolio, 2005-06

Table 4.40: AstraZeneca’s cancer R&D product pipeline, 2007

Table 4.41: Novartis’ cancer product portfolio, 2005-06

Table 4.42: Novartis’ cancer R&D product pipeline, 2007

Table 4.43: Pfizer’s cancer product portfolio, 2005-06

Table 4.44: Pfizer’s cancer R&D product pipeline, 2007

Table 4.45: Schering-Plough’s cancer product portfolio, 2005-06

Table 4.46: Schering-Plough’s cancer R&D product pipeline, 2007

Table 4.47: Lilly’s cancer product portfolio, 2005-06

Table 4.48: Lilly’s cancer R&D product pipeline, 2007

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.